Perspectives and challenges in patient stratification in Alzheimer's disease.

Carla Abdelnour, Federica Agosta, Marco Bozzali, Bertrand Fougère, Atsushi Iwata, Ramin Nilforooshan, Leonel T Takada, Félix Viñuela, Martin Traber

Journal: Alzheimer's research & therapy 2022;14(1):112

PMID: 35964143

Abstract

BACKGROUND

Patient stratification is the division of a patient population into distinct subgroups based on the presence or absence of particular disease characteristics. As patient stratification can be used to account for the underlying pathology of a disease, it can help physicians to tailor therapeutic interventions to individuals and optimize their care management and treatment regime. Alzheimer's disease, the most common form of dementia, is a heterogeneous disease and its management benefits from patient stratification in clinical trials, and the development of personalized care and treatment strategies for people living with the disease.

MAIN BODY

In this review, we discuss the importance of the stratification of people living with Alzheimer's disease, the challenges associated with early diagnosis and patient stratification, and the evolution of patient stratification once disease-modifying therapies become widely available.

CONCLUSION

Patient stratification plays an important role in drug development in clinical trials and may play an even larger role in clinical practice. A timely diagnosis and stratification of people living with Alzheimer's disease is paramount in determining people who are at risk of progressing from mild cognitive impairment to Alzheimer's dementia. There are key issues associated with stratifying patients which include the heterogeneity and complex neurobiology behind Alzheimer's disease, our inadequately prepared healthcare systems, and the cultural perceptions of Alzheimer's disease. Stratifying people living with Alzheimer's disease may be the key in establishing precision and personalized medicine in the field, optimizing disease prevention and pharmaceutical treatment to slow or stop cognitive decline, while minimizing adverse effects.

© 2022. The Author(s).

Address: Universidad Autónoma de Barcelona, Barcelona, Spain. [email protected].; Unit of Neurology and Neuroimaging Research Unit, IRCCS San Raffaele Scientific Institute, and Vita-Salute San Raffaele University, Milan, Italy.; Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.; Department of Geriatric Medicine, Tours University Hospital, Tours, France.; Department of Neurology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan.; Abraham Cowley Unit, Surrey and Borders Partnership NHS Foundation Trust, Chertsey, UK.; University of Surrey, Guildford, UK.; UK Dementia Research Institute - Care Research and Technology Centre, London, UK.; Cognitive and Behavioral Neurology Unit, Department of Neurology, University of São Paulo, São Paulo, Brazil.; Instituto Neurológico Andaluz, Hospital Victoria Eugenia/Unidad Deterioro Cognitivo, Hospital Virgen Macarena/Faculty of Medicine, University of Seville, Seville, Spain.; Product Development Medical Affairs, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.